scispace - formally typeset
S

Sylvain Lefort

Researcher at BC Cancer Agency

Publications -  34
Citations -  6316

Sylvain Lefort is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Cancer & Leukemia. The author has an hindex of 14, co-authored 30 publications receiving 5683 citations. Previous affiliations of Sylvain Lefort include French Institute of Health and Medical Research & Curie Institute.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.

TL;DR: It is demonstrated that LC3B, a protein involved in autophagosome formation, is a reliable marker of poor prognosis in TN BC, validating this prognostic value at both the mRNA and protein levels in several independent cohorts and the inhibition of autophagy is identified as a promising therapeutic strategy for TN BC patients.
Journal ArticleDOI

Detection, characterization and regulation of antisense transcripts in HIV-1

TL;DR: The existence of antisense transcription exists in HIV-1 in the context of infection for the first time and a better characterization of the transcript and its regulation is provided.
Journal ArticleDOI

Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells

TL;DR: In this article, the authors presented the first formal evidence of the shared and independent ability of basal cells and luminal progenitors, isolated from normal human mammary tissue and transduced with a single oncogene (KRAS(G12D)), to produce serially transplantable, polyclonal, invasive ductal carcinomas within 8 weeks of being introduced either subrenally or subcutaneously into immunodeficient mice.